AUTHOR=Fisher Elizabeth S. , Chen Yanan , Sifuentes Mikaela M. , Stubblefield Jeremy J. , Lozano Damian , Holstein Deborah M. , Ren JingMei , Davenport Matthew , DeRosa Nicholas , Chen Tsung-pei , Nickel Gerard , Liston Theodore E. , Lechleiter James D. TITLE=Adenosine A1R/A3R agonist AST-004 reduces brain infarction in mouse and rat models of acute ischemic stroke JOURNAL=Frontiers in Stroke VOLUME=Volume 1 - 2022 YEAR=2022 URL=https://www.frontiersin.org/journals/stroke/articles/10.3389/fstro.2022.1010928 DOI=10.3389/fstro.2022.1010928 ISSN=2813-3056 ABSTRACT=
Acute ischemic stroke (AIS) is the second leading cause of death globally. No Food and Drug Administration (FDA) approved therapies exist that target cerebroprotection following stroke. Our group recently reported significant cerebroprotection with the adenosine A1/A3 receptor agonist, AST-004, in a transient stroke model in non-human primates (NHP) and in a preclinical mouse model of traumatic brain injury (TBI). However, the specific receptor pathway activated was only inferred based on